Benzinga | Dec 21, 2020 06:39AM EST

Jefferies Downgrades Epizyme to Hold, Lowers Price Target to $14

Jefferies downgrades Epizyme (NASDAQ:EPZM) from Buy to Hold and lowers the price target from $18 to $14.